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Available online 11 May 2016Vaccines are a critical clinical tool in preventing illness and death due to infectious diseases and are regularly ad-
ministered to children and adults across the globe. In order to obtain full protection from many vaccines, an in-
dividual needs to receive multiple doses over the course of months. However, vaccine administration in
developing countries is limited by the difﬁculty in consistently delivering a second or third dose, and some vac-
cines, including the inactivated polio vaccine (IPV), must be injectedmore than once for efﬁcacy. In addition, IPV
does not remain stable over time at elevated temperatures, such as those it would encounter over time in the
body if it were to be injected as a single-administration vaccine. In this manuscript, we describe microspheres
composed of poly(lactic-co-glycolic acid) (PLGA) that can encapsulate IPV along with stabilizing excipients and
release immunogenic IPV over the course of several weeks. Additionally, pH-sensitive, cationic dopants such as
Eudragit E polymer caused clinically relevant amounts of stable IPV release upon degradation of the PLGAmatrix.
Speciﬁcally, IPV was released in two separate bursts, mimicking the delivery of two boluses approximately one
month apart. In one of our top formulations, 1.4, 1.1, and 1.2 doses of the IPV serotype 1, 2, and 3, respectively,
were released within the ﬁrst few days from 50 mg of particles. During the delayed, second burst, 0.5, 0.8, and
0.6 doses of each serotype, respectively, were released; thus, 50 mg of these particles released approximately
two clinical doses spaced amonth apart. Immunization of rats with the leadingmicrosphere formulation showed
more robust and long-lasting humoral immune response compared to a single bolus injection andwas statistical-
ly non-inferior from two bolus injections spaced 1month apart. By minimizing the number of administrations of
a vaccine, such as IPV, this technology can serve as a tool to aid in the eradication of polio and other infectious
diseases for the improvement of global health.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Vaccines have been essential in combating infectious diseases in
both children and adults. However, for many vaccines, multiple doses
must be administered over the course of months, which can be chal-
lenging in developing countrieswhere vaccine administration is limited
by patient access. For example, among incompletely vaccinated chil-
dren, N40% receive at least one dose of the diphtheria-tetanus-pertussis
vaccine but do not receive all three recommended doses, therefore
remaining unprotected [1]. In order to achieve better vaccination cover-
age, especially in the developing world, the World Health Organization
(WHO) Expanded Program for Immunization (EPI) suggests that an
ideal vaccine should be heat-stable, require only a single shot, and be
easy to administer [2]. The requirements for stability and single admin-
istration are challenging for many vaccines, such as the poliovirusambridge, MA 02139, USA.
c@mit.edu (A. Jaklenec).
. This is an open access article undervaccine, which has been shown to have very poor thermal stability [3].
The two types of polio vaccines currently being used are the oral polio
vaccine (OPV), a live attenuated virus, and the inactivated polio vaccine
(IPV). IPV, while much safer than OPV with no risk of reversion to a
disease-causing virus [4], must be injected more than once for efﬁcacy
[5]. This can be prohibitive to protection and eradication efforts, as stud-
ies in some regions of the world have found that coverage for a second
dose of vaccines ismuch lower than that for the ﬁrst dose [6]. Therefore,
a formulation that can deliver the equivalent of two ormore boluses of a
vaccine with only a single administration would be very valuable for
disease eradication [2].
However, single administration of vaccines and especially IPV is
challenging because of its poor thermostability [7]. In general, IPV is ad-
ministered in the D-antigen conformation, which is used to evaluate
clinical formulations and is characteristic of infective viruses; over
time at high temperature, it converts to the C-antigen conformation,
which does not confer protective immunity. If injected only once into
a patient and retained long-term in a local depot, IPV would need tothe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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sponse after incubation inside the body at 37 °C for several months in
the presence of various biological factors as well as the depot material.
Work has been done on identifying various stresses that affect IPV sta-
bility [8], screening excipients that will stabilize IPV through drying
and storage conditions [9,10], and improving the immunogenicity of
IPV through the use of adjuvants [11]. However, these studies do not ad-
dress the fact that multiple injections are required for protection.
Controlled release microspheres are a promising technology for sin-
gle-injection vaccines such as IPV. However, to our knowledge, no stud-
ies have previously been published on controlled release of IPV from
injectable, biodegradable microspheres. Biocompatible, degradable mi-
crospheres can be injected once and remain in the body as a depot,
with degradation of the material controlling the timing of vaccine re-
lease [12,13]. Poly(lactic-co-glycolic acid) (PLGA) is among the most
well-studied materials for microsphere formulations. As a result of its
biocompatibility, PLGA has been a component of a number of FDA-
approved devices [14,15]. In certain cases, large, hydrophilic macromol-
ecules, such as proteins and particularly virus particles such as IPV, can
be designed to be released from PLGA particles immediately in an initial
burst of release, followed by slow or no release while the polymer be-
gins to degrade by bulk erosion, and ﬁnally a second burst of accelerated
release [16–18]. Moreover, extended presentation of antigens after in-
jection, as would be expected from a depot of injected microspheres,
has been shown to improve the immune response compared to a
bolus [19]. Design of PLGA microspheres to exhibit pulsatile release
could potentially lead to even better response, as it would mimic the
2–3 injections currently used in the clinic [12].
Despite their promise as a tool for disease eradication, PLGA micro-
particle-based systems present many points at which IPV can be
destabilized during the formulation process and over the course of re-
lease at body temperature. Moreover, IPV is composed of three sero-
types of inactivated poliovirus, each of which may respond differently
to stresses. Various excipients, including carbohydrates, amino acids,
and salts have been studied as potential stabilizers for IPV, with a com-
bination of a sugar or polyol, monosodium glutamate (MSG), and mag-
nesium chloride (MgCl2) greatly increasing IPV thermostability in the
dry state [9]. Here, we study various excipients from these classes to as-
sess their ability to protect the stability of all three IPV serotypes during
processing, drying, and incubation in a wet and 37 °C environment over
time. We further use a water-in-oil-in-oil (w/o1/o2) double emulsion
method in order to co-encapsulate these small-molecule excipients
with IPV in PLGA microspheres with minimal initial leakage [20]. We
then assessed their efﬁcacy in stabilizing IPV in PLGA microspheres
and use a polycationic dopant, Eudragit E, to modulate PLGA degrada-
tion as well as buffering the acidic PLGA degradation products, thereby
achievingmultiple bursts of IPV release over time. Finally, microspheres
composed of PLGA and Eudragit E, encapsulating IPV and stabilizing ex-
cipients, were injected intramuscularly into rats to show non-inferior
humoral immune response compared to bolus injections spaced 1
month apart.
2. Materials and methods
2.1. Materials
Trivalent inactivated polio vaccine (tIPV) stocks were provided by
Statens Serum Institut (SSI; Copenhagen, Denmark) with starting con-
centrations of 327 DU/mL, 70 DU/mL, and 279 DU/mL of type 1, 2, and
3, respectively (Brünhilde strain type 1,MEF-1 strain type 2, and Saukett
strain type 3). D-antigen content of samples was assessed using the
monoclonal D-antigen enzyme-linked immunosorbent assay (ELISA)
kit purchased from SSI. Poly(D,L-lactic-co-glycolic acid) (PLGA) with av-
erage molecular weight and lactide-to-glycolide ratios of 12 kDa and
50:50 (PLGA502H) and Eudragit® E PO (EPO) were purchased from
Evonik (Essen, Germany). Gelatin from cold water ﬁsh skin, D-sorbitol,D-sucrose, D-trehalose, maltodextrin, monosodium glutamate (MSG),
magnesium chloride hexahydrate (MgCl2), magnesium hydroxide
(Mg(OH)2), heavy mineral oil, and the surfactant Span® 80 were
purchased from Sigma Aldrich (St. Louis, MO). AlexaFluor® 680
succinimidyl ester was from Life Technologies (Carlsbad, CA). Serum
binding antibody titers were measured by indirect ELISA using mono-
clonal mouse antibodies speciﬁc for D-antigenic type 1 (HYB295-15-
02), type 2 (HYB294-06-02), or type 3 (HYB300-05-02) poliovirus
from Thermo Scientiﬁc Pierce (Life Technologies Corporation, Grand
Island, NY) and polyclonal goat anti-rat IgG antibody conjugated
with horse radish peroxidase (HRP) from Abcam (Cambridge, MA).
SigmaFast OPD (o-phenylene diamine) peroxidase substrate was
purchased from Sigma.
2.2. IPV thermostability studies
To assess stability of IPV after incubation at 37 °C, tIPV was concen-
trated using 0.5-mL Amicon® Ultracel® centrifugal ﬁlters (Merck
Millipore Ltd., Billerica, MA) with 100-kDa molecular weight cutoff.
Each ﬁlter was blocked with 2.5% solution of gelatin by centrifugation
at 14,000 rcf for 10 min and then removal of the gelatin retentate
from the ﬁlter. In 0.5-mL increments, 2 mL of tIPV stock solution was
concentrated by centrifuging at 14,000 rcf for 10min. Following concen-
tration, the IPV retentate was diluted with 0.5 mL sterile distilled water
and concentrated once more in order to remove the small-molecule
components in the tIPV medium. Using this method, 2 mL tIPV stock
was concentrated to 19 ± 1 μL with 148-, 150-, and 145-fold increase
in type 1, 2, and 3 concentration, respectively, from the tIPV stock con-
centration (Supplementary Fig. S1), and thiswill be referred to hereafter
as IPVconc.
The IPVconc was then diluted to 16 DU/mL, 3.4 DU/mL, and
13.6 DU/mL type 1, 2, and 3, respectively, in sterile distilled water.
This dilute IPV solution was then mixed 1:1 (v/v) with a sterile solu-
tion of an excipient or excipient mixture in water (see Table 1). The
ﬁnal IPV concentration in all groups, assuming no loss of D-antigenic-
ity during the ﬁltration and concentration processes, was 8 DU/mL,
1.7 DU/mL, and 6.8 DU/mL type 1, 2, and 3, respectively. Because
lower IPV concentrations were found to be more difﬁcult to stabilize
(Supplementary Fig. S2), excipient screening was carried out at a rel-
atively low IPV concentration, corresponding to approximately ten-
fold lower concentration than the normal concentration used for clin-
ical administration (80 DU/mL, 16 DU/mL, and 64 DU/mL). IPV/excip-
ient mixtures were then aliquoted into sealed vials and stored at 37 °C
on a tube revolver. At predetermined time points, some aliquots were
removed and analyzed by ELISA. All results were normalized to the
starting D-antigen content of the formulation before storage at 37 °C.
2.3. IPV processing stability studies: water-in-oil emulsion
IPV stability was assessed after exposure to aqueous/organic solvent
interfaces and the physical mixing processes used to form water-in-oil
emulsions. Nineteen microliters of IPVconc was mixed with 10 μL of
water or aqueous solution of excipients at a 100:1 excipient:IPV mass
ratio, and the mixture was added to a solution of 25 mg PLGA502H in
1 mL dichloromethane. These were emulsiﬁed via sonication on ice at
20% amplitude for 30 s. Two milliliters of ELISA sample dilution buffer
(1× PBS with 1% TritonX-100, 1% bovine serum albumin [BSA], and
0.001% phenol red) was added to the emulsion and mixed well by
vortexing. The organic dichloromethane layer was then evaporated
over 3 h of stirring, and the remaining aqueous phase was analyzed
for D-antigen content by ELISA.
2.4. IPV processing stability studies: vacuum-drying
Tenmicroliterswater or aqueous solution of excipientswas added to
19 μL of IPVconc using a 100:1 excipient:IPVmass ratio. This ﬁnal volume
Table 1
Stabilizing excipients tested for IPV thermostability studies.
Sugars/sugar alcohols Amino acids Proteins Divalent salt
Mean IPV D-antigen recovery after
1 month at 37 °C (%)
Type 1 Type 2 Type 3
– – – – 29% 86% 66%
10% sorbitol – – – 1% 0% 31%
10% sorbitol 8.5% MSG – – 21% 86% 31%
10% sorbitol 8.5% MSG – 8.5% MgCl2 45% 83% 38%
4% sorbitol 3.4% MSG – 3.4% MgCl2 31% 77% 50%
2% sorbitol 1.7% MSG – 1.7% MgCl2 32% 73% 52%
10% sucrose – – – 0% 0% 16%
10% sucrose 8.5% MSG – – 24% 79% 27%
10% sucrose 8.5% MSG – 8.5% MgCl2 64% 78% 37%
4% sucrose 3.4% MSG – 3.4% MgCl2 42% 69% 54%
2% sucrose 1.7% MSG – 1.7% MgCl2 25% 68% 54%
10% trehalose – – – 24% 79% 72%
10% trehalose 8.5% MSG – – 27% 56% 59%
10% trehalose 8.5% MSG – 8.5% MgCl2 59% 51% 52%
4% trehalose 3.4% MSG – 3.4% MgCl2 38% 80% 71%
2% trehalose 1.7% MSG – 1.7% MgCl2 16% 78% 32%
10% maltodextrin – – – 3% 33% 2%
10% maltodextrin 8.5% MSG – – 62% 80% 55%
10% maltodextrin 8.5% MSG – 8.5% MgCl2 70% 83% 65%
4% maltodextrin 3.4% MSG – 3.4% MgCl2 53% 76% 61%
2% maltodextrin 1.7% MSG – 1.7% MgCl2 38% 79% 53%
– – 10% gelatin – 0% 49% 18%
– – 4% gelatin – 0% 54% 32%
– – 2% gelatin – 10% 64% 41%
103S.Y. Tzeng et al. / Journal of Controlled Release 233 (2016) 101–113was placed in a vacuum for 1 h at room temperature to simulate the
ﬁnal drying of microspheres. The dried product was then redissolved
in ELISA sample dilution buffer and tested via ELISA. Percent recovery
was calculated by normalizing the D-antigen measurement to that of a
formulation prepared in the sameway but left liquid rather than drying
under vacuum.
2.5. IPV pH-sensitivity studies
Salt solutions of varying pHwere prepared. Because of differences in
the IPV-stabilizing properties of different salts, 1× PBS was used for all
solutions, with small amounts of 1M hydrochloric acid (HCl) or 1 M so-
dium hydroxide (NaOH), rather than other buffers optimized for very
high or low pH. tIPV was diluted 1:200 in solutions of pH 1, 4.5, 6, 7.4,
8, or 9 and stored at either 4 °C or 37 °C. After 7 days, the dilute IPV so-
lutionswere neutralizedwith either HCl or NaOH, andD-antigen recov-
ery was measured via ELISA.
2.6. Emulsion microsphere formulations
A double emulsion method was used to encapsulate IPV along with
stabilizing excipients in PLGA-based microspheres. Because many of
the excipients used are salts and other small molecules, a water-in-oil-
in-oil (w/o1/o2) method was used to minimize the diffusion of excipi-
ents out of the particles during the formulation process. The aqueousTable 2
Excipients co-encapsulated with IPV in PLGA microspheres. Percentages refer to the mass ratio
Formulation Number-weighted mean diameter (μm) Sugars/sugar alcohols
F1 5.8 ± 3.6 –
F2 10.7 ± 3.4 8% sucrose
F3 10.2 ± 3.3 8% maltodextrin
F4 10.3 ± 3.4 8% sucrose
F5 8.7 ± 3.5 8% sucrose
F6 8.3 ± 3.5 8% maltodextrin
F7 7.7 ± 3.4 8% maltodextrin
F8 11.2 ± 3.4 8% maltodextrin
F9 10.5 ± 3.3 8% maltodextrin(w) phase consisted of 2 mL tIPV, concentrated to form 19 μL of IPVconc
and mixed with 10 μL of a solution of excipient(s) in water. All excipi-
ents and excipient combinations tested are listed in Table 2. The ﬁrst
oil (o1) phase was prepared by dissolving 25 mg PLGA502H in 1 mL di-
chloromethane (DCM). In some formulations, EPOwas also dissolved in
the o1 phase. For all formulations, the tIPV was 0.2% of the ﬁnal formu-
lation by mass. The second oil phase (o2) consisted of heavy mineral
oil with 3% (v/v) Span® 80 surfactant.
To form the ﬁrst emulsion, the w phase was added to the o1 phase,
and the mixture was sonicated at 20% amplitude for 30 s. For formula-
tions containing Mg(OH)2, solid Mg(OH)2 was ﬁrst dispersed in the o1
phase by sonication before adding w and sonicating again. To form the
second emulsion, 1mL o2 was added to thew/o1 emulsion and vortexed
for 5 s at 3500 rpm. This w/o1/o2 was then poured into stirring heavy
mineral oil (0.4% ﬁnal surfactant concentration). The entire suspension
was stirred for 3 h at room temperature to allow complete DCM
extraction and evaporation. Particles were collected by centrifugation
at 200 rcf for 3 min at 4 °C, washed three times with hexanes, and
dried for 1 h under vacuumat room temperature. All DCMwas expected
to have evaporated after 3 h stirring during microsphere formulation
[21,22], aided in part by its high solubility with the mineral oil continu-
ous phase. All hexanes, which were present only on external surfaces of
the particles, were vaporized upon exposure to high vacuum during
drying. The dry microspheres were either resuspended in buffer for
immediate use or stored dry at 4 °C with desiccant until use.of excipients to the PLGA microspheres.
Amino acids Proteins Divalent salt Other
– 8% gelatin – –
6.8% MSG – 6.8% MgCl2 –
6.8% MSG – 6.8% MgCl2 –
6.8% MSG – 6.8% MgCl2 5% Mg(OH)2
6.8% MSG – 6.8% MgCl2 0.4% L-arginine
6.8% MSG – 6.8% MgCl2 7.5% EPO
6.8% MSG – 6.8% MgCl2 5% EPO
6.8% MSG – 6.8% MgCl2 3% EPO
6.8% MSG – 6.8% MgCl2 5% EPO, 0.4% arginine
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The pH and release kinetics of PLGA particles was assessed simulta-
neously. For release kinetics, IPV was labeled with AlexaFluor® 680
(AF680) formeasurement of total IPV release by ﬂuorescence detection.
tIPV stock was concentrated to IPVconc as described above using centrif-
ugal ﬁlters. The ﬁnal product was washed three times with 0.1 M car-
bonate/bicarbonate buffer (pH 8.9) and collected into a tube. AF680
succinimidyl ester dye was dissolved in DMSO at 5 mg/mL and added
to the IPV suspended in carbonate/bicarbonate buffer, for a ﬁnal dye:IPV
molar ratio of approximately 300:1. The resulting mixture was
protected from light and incubated at room temperature for 1 h on a
tube revolver. Free dye was removed from the reaction using a PD-10
pre-packed column with Sephadex G-25 beads, equilibrated with a
9:1 (v/v) water-to-DMSO mixture. The product was then puriﬁed
again in a PD-10 column equilibrated with water alone. This ﬁnal prod-
uct (AF680-IPV) was lyophilized overnight. Before use, the dry powder
was resuspended in water to the same starting volume as IPVconc and
was used at the same concentration to make emulsion microspheres.
All formulations containing AF680-IPV were kept out of direct light. La-
beling efﬁciency of the ﬂuorophore was assessed via NanoDrop (Ther-
mo Scientiﬁc) by measuring the absorbance of the protein-dye
conjugate at 679 nm (AF680 absorbance peak, molar extinction coefﬁ-
cient ε = 184,000 cm−1 M−1) and 280 nm (protein absorbance peak,
estimated ε = 5580 cm−1 M−1). AF680-IPV with a 76:1 molar ratio of
dye:virion was used. Similar procedures were used to label BSA
(AF680-BSA), with a ﬁnal dye:protein molar ratio of 3:1.
For release studies, microspheres containing AF680-IPV were resus-
pended at 10 mg/mL in release buffer containing 1× PBS with 0.2% BSA
and 0.02% sodium azide. Tubes containing themicroparticle suspension
were incubated at 37 °C on a tube revolver. At predetermined time
points, tubes of particles were removed from the incubator and centri-
fuged at 1500 rcf at 4 °C for 5min. The particles in each tubewere resus-
pended in release buffer, vortexed, and returned to 37 °C until the next
time point. Supernantants were measured in a black-walled, clear-bot-
tom 96-well plate using an Inﬁnity® M1000 Pro microplate reader
(Tecan, Mannëdorf, Switzerland), with excitation/emission of 679 nm/
702 nm, respectively. The pH of the supernant was also measured
using pH strips and reported as the average pH value measured for all
the samples ± standard deviation.
2.8. Release studies for unlabeled IPV-containing microspheres
IPV microspheres were resuspended at 10–15 mg/mL in release
buffer containing 1× PBS with 50 mM HEPES, 0.2% BSA, 0.001% phenol
red, and 0.02% sodium azide. The same buffer was used for all micro-
sphere formulations. Tubes containing the microparticle suspension
were incubated at 37 °C on a tube revolver. At predetermined time
points, tubes of particles were removed from the incubator and centri-
fuged at 1500 rcf at 4 °C for 5 min. The supernatant of each tube was re-
moved and stored at 4 °C for up to 1 week before analysis. The particles
in each tubewere resuspended in release buffer, vortexed, and returned
to 37 °C until the next time point. D-antigen in the collected superna-
tants was measured via ELISA.
2.9. Microsphere characterization
The amount of IPV encapsulated in microspheres was measured
using a method similar to that reported by Kim et al. [23]. Five milli-
grams ofmicrospheres was dissolved in 1mL of DCM. After the polymer
had dissolved, leaving small amounts of organic-insoluble solids, the
suspension was centrifuged at 15,000 rcf for 15 min, and the polymer-
containing DCM solutionwas removed, similar to themethod described
by. The precipitate was washed three times with DCM to ensure com-
plete removal of thewater-insoluble polymer(s). Residual DCMwas re-
moved from the precipitate by vacuum. The precipitate, which includedIPV, was then dissolved in 1 mL of 1× PBS. The concentration of IPV in
the aqueous fraction was measured by ELISA using polyclonal antibod-
ies isolated from rabbits immunized with denatured IPV (see Supple-
mentary methods). Three (n = 3) samples were measured for each
microsphere batch, and encapsulation efﬁciency is reported as
mean ± standard deviation.
Microspheres were imaged with scanning electron microscopy
(SEM).Micrographswere obtained using a FEI XL30 FEG Environmental
SEMwith backscatter detector. Microsphere size was measured using a
Multisizer 3 Coulter Counter (Beckman Coulter).
2.10. Immune response to IPV in rodents
Female Wistar rats aged 8–12 weeks were anaesthetized with
isoﬂurane and immunized by intramuscular (IM) injection in the hind
quadriceps. Experimental groups tested were free IPV as a single
bolus; free IPV as two boluses, spaced four weeks apart; controlled-
released microspheres containing encapsulated IPV and stabilizing ex-
cipients; and free IPV as a single bolus alongside blank microspheres
containing only stabilizing excipients. For microsphere groups, the par-
ticles were resuspended in saline using amethod similar to those previ-
ously reported [24,25] before injection. For all groups, the same total D-
antigen IPV (24 DU type 1, 4.8 DU type 2, and 19.2 DU type 3) was
injected. The amount of IPV in microspheres was calculated from the
total D-antigen IPV released in vitro, as measured by ELISA. All groups
included n = 10 animals. Blood was collected from the lateral tail vein
of all animals at 2 week intervals. The whole blood was clotted, and
the serum was separated via centrifugation at 2000 rcf for 10 min at
4 °C and kept frozen at −20 °C until analysis. For negative control,
two untreated rats of the same strain and age were exsanguinated and
their serum pooled.
To measure IPV-speciﬁc binding antibody (IgG) titers, monoclonal
mouse anti-poliovirus antibodies from Thermo Scientiﬁc Pierce, speciﬁc
for the D-antigenic form of type 1, 2, or 3 poliovirus, were diluted
1:1000 in 100 mM carbonate-bicarbonate buffer (pH 9.6) and used to
coat 96-well plates overnight at 4 °C. Unbound antibodies were re-
moved with wash buffer (1× PBS + 0.05% Tween 20), and plates
were blocked for 1 h at 37 °C with buffer containing 5% non-fat dry
milk in 1× PBS + 0.05% Tween 20. Blocking buffer was removed, and
IPV, diluted to 10 DU/mL in blocking buffer, was added to the wells
and incubated at room temperature for 2 h. Unbound IPV was washed
from the plates, and serum samples, serially diluted in blocking buffer,
was added to the wells and incubated for 2 h at 37 °C. Serum samples
were washed from the plate, and polyclonal goat anti-rat IgG HRP-
conjugated antibody, diluted 1:3000 in blocking buffer, was added to
thewells and incubated for 1 h at 37 °C. Unbound antibodywaswashed
from the plate, and OPD peroxidase substrate was added to the wells
and allowed to develop for 30 min at room temperature. The reaction
was stopped by addition of 1 M H2SO4, and absorbance of each well
was read at 490 nm using a Tecan multiplate reader. Titer is reported
as the lowest dilution that gave an absorbance reading ≥ 2-fold higher
than the negative control at the same dilution.
Free IPV injected as two boluses, spaced four weeks apart, was used
as the positive control. At each time point, the antigen-speciﬁc IgG titers
of all four groups were compared using a one-way analysis of variance
(ANOVA) with a post hoc Dunnett test for multiple comparisons to the
positive control.
3. Results and discussion
3.1. Excipients stabilize liquid IPV formulations over time at physiological
temperature
Without any additives, IPV rapidly loses D-antigen content when
stored at 37 °C (Table 1, Fig. 1A), with 29 ± 1%, 86 ± 3%, and 66 ±
11% recovery of serotypes 1, 2, and 3, respectively, after 1 month of
Fig. 1. IPV recovery after long-term incubation at 37 °Cwas improved by excipients. IPV recovery in only bufferwas poor after incubation at 37 °C, particularly for serotype 1 (A). However,
addition of sugar-based excipients, particularly in combination with MSG andMgCl2, greatly improved the 1-month stability of type 1 IPV (B) in a concentration-dependent manner (C).
After 56 days of incubation, sucrose- and maltodextrin-based formulations resulted in N20% and N35% recovery, respectively, of all three serotypes (D).
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lize IPV, either by themselves or in combination with monosodium glu-
tamate (MSG) and/orMgCl2. Of the four, trehalosewas the only one that
did not have a negative effect on IPV stability at the concentration tested
when used as the sole excipient, with 23.9±0.9%, 79±2%, and 72±4%
recovery of types 1, 2, and 3, respectively after 1 month. Most of the
sugars gave signiﬁcantly better results in combination with MSG, and
all of them gave the best results after also adding MgCl2. It is likely
that each component of the combined formulation has a differentmech-
anismof interactionwith IPV, resulting in thebest thermostabilitywhen
all three are used together. With a focus on type 1, which was the least
stable serotype in initial studies aswell as contributing to a high propor-
tion of paralytic poliomyelitis cases [5], sucrose, maltodextrin, and tre-
halose were the most effective polyols in combination with both MSG
and MgCl2, with 64 ± 3%, 70 ± 6%, and 59 ± 3% recovery of type 1, re-
spectively, after 1 month at 37 °C (Fig. 1B).
This protective effect was concentration-dependent, as the recov-
ered D-antigenicity decreased with decreasing excipient concentration
(Fig. 1C). Although maltodextrin, sucrose, and trehalose all gave similar
results at high concentrations and in combinationwithMSG andMgCl2,
it is important to note that the thermostabilizing effects of the latter two
polyol-based formulations dropped 2.5- to 3.6-fold when their concen-
tration was reduced to 20% of the initially tested formulations. In con-
trast, the formulation containing maltodextrin, MSG, and MgCl2 lost
less than half of its efﬁcacy when the concentration was reduced to
20%, resulting in ﬁnal D-antigen recovery of 38 ± 5%, 79 ± 2%, and53 ± 3% of types 1, 2, and 3, respectively, after 1 month at 37 °C. After
2 months of incubation at 37 °C with a high concentration of maltodex-
trin, MSG, and MgCl2, IPV D-antigen remained fairly stable, with 54 ±
6%, 58 ± 8%, and 40 ± 5% recovery, respectively (Fig. 1D). Therefore,
this formulation was used for further microsphere optimization.
Generally, gelatin did not show stabilizing effects in our hands, with
type 1 IPV completely undetectable within 1 month of incubation with
10% gelatin (Fig. 1C). SomeD-antigenwas recoveredwhen a lower con-
centration of gelatin was used, suggesting that, under the conditions of
this study, gelatin in fact had a destabilizing effect on IPV. It should be
noted that many of the polyols alone seemed to have this effect as
well and only showed optimal effects in combination with other excip-
ients; however, these excipients could not be tested in combination
with gelatin, as the addition of MSG and MgCl2 appeared to salt out
the protein, resulting in the formation of either a precipitate or a sepa-
rate phase within the vials. Any trace gelatin left in the IPVconc due to
the initial ﬁlter-blocking step seemed to have been a negligible amount
and caused no measurable difference in IPV recovery (Supplementary
Fig. S3).
3.2. IPV processing stability studies: water-in-oil emulsion
For microspheres to be effective, IPVmust survive the encapsulation
process, including the contact with organic solvents and physical
mixing stresses associated with double-emulsion. To test this, IPV was
sonicated on ice at low energy for 30 s, then extracted into aqueous
Fig. 3. Gelatin and sugar-based excipients protect IPV during dehydration. Without
excipients, very little IPV survives being dried under vacuum for 1 h. When mixed ﬁrst
with gelatin, carbohydrates, or a combination of carbohydrates with MSG and MgCl2,
IPV recovery improves drastically. All experimental groups are statistically signiﬁcant
compared to IPV dried without excipients (b 0.0001).
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process. This test was not carried out in the presence of PLGA, because
any methods used to extract, degrade, or dissolve the PLGA in order to
remove it from the aqueous system also caused denaturation of the
IPV. However, while PLGA in the system could affect the sonication pro-
cess and the IPV recovery, we were still able to compare the relative ef-
fects of various excipient formulations on the stability of IPV during
sonication. As in previous studies, type 1 IPV had the lowest recovery
of the three serotypes (Fig. 2). The inclusion of small polyols, amino
acids, or MgCl2 salt had no signiﬁcant effect on IPV stability after emul-
siﬁcation; only gelatin showed a statistically signiﬁcant (p b 0.01) posi-
tive effect on IPV recovery.
It is unsurprising that gelatin had a positive effect on IPV stability
during the emulsion process, as one of the major stresses at this step
is expected to be the increase in interfacial tension between the oil (or-
ganic) and water (aqueous) phases, which can cause denaturation and
promote aggregation [26,27]. Like other proteins, gelatin is amphiphilic
in nature and can shield proteins and vaccines from damage at the oil-
water interfaces [28,29]. Sugars, amino acids, and salts did not provide
as much protection for IPV during emulsion, although the increase in
viscosity of the aqueous phase caused by the addition of such solutes
could have contributed to small increases in stability.
3.3. IPV processing stability studies: vacuum-drying
Microspheres were dried in the ﬁnal step of formulation in order to
remove excess organic solvents and water and to accurately measure
the particle yield. Although lyophilization has been previously used for
dried preparations of IPV, many formulations tested in the literature
have shown that vacuum-drying, without the initial freezing step of ly-
ophilization, results in better preservation of D-antigenicity [9].
In our studies, we show that certain excipients or combinations of
excipients can drastically improve IPV stability during the drying pro-
cess. Only 1.0 ± 0.2%, 15 ± 3%, and 1.8 ± 0.3% of D-antigen for type 1,
2, and 3, respectively, was recovered after drying IPV without any addi-
tional excipients. All of the excipients tested signiﬁcantly improved IPV
recovery during drying (Fig. 3, p b 0.001 for all compared to no excipient
control). Gelatin was again effective in preserving D-antigenicity during
drying, in keeping with other work that has found relatively highFig. 2. Gelatin protects IPV from damage during sonication. Approximately 40–50% of IPV
activity is lost during sonication without addition of excipients. Although small molecule
excipients like sugars, salts, and amino acids have some protective effect on stability
during this step, gelatin did signiﬁcantly improve stability when included in the IPV
formulation.concentrations of proteins to prevent denaturation during lyophiliza-
tion or drying by steric hindrance [30]. However, all of the carbohy-
drate-based excipients also conferred protection, in agreement with
results by others showing the ability of sugars to protect proteins, vac-
cines, or nanoparticles from denaturation during drying [31–33].
Of the carbohydrates, trehalose and maltodextrin conferred the
most protection on their own. When dried with 10% trehalose, 73 ±
6%, 84 ± 5%, and 59 ± 5% of types 1, 2, and 3, respectively, was recov-
ered. When dried with 10% maltodextrin, 88 ± 4%, 99 ± 7%, and
88 ± 5% recovery was observed. However, with the addition of 8.5%
MSG and 8.5% MgCl2, recovery rates increased for the other sugars as
well, with signiﬁcant improvements in types 1 and 3 recovery for
sorbitol- and sucrose-based formulations. It is likely thatMgCl2 changed
the solubility of the proteins in the IPV capsid [34], which resulted here
in higher recovery after dehydration. These small changes in relative hy-
dration are expected to have a strong effect, as vacuum-drying is ex-
pected to leave some residual water after dehydration [9].
3.4. Sugar-based excipient formulations partially stabilize IPV in PLGA
microspheres
A number of candidates appeared to be promising excipients for IPV
stability, with gelatin yielding the best results for protection during dry-
ing and emulsiﬁcation and sugar-based formulations yielding the best
results for IPV incubation over time at 37 °C. In order to evaluate the
long-term, controlled release of stable IPV frommicrospheres, we mea-
sured IPV D-antigen activity over time released from PLGA micro-
spheres when co-encapsulated with either gelatin; sucrose, MSG, and
MgCl2; ormaltodextrin,MSG, andMgCl2, all of whichwere top formula-
tions in at least one of the initial stability studies. Representative scan-
ning electron micrographs showed the expected spherical shape and
generally smooth morphology for these formulations (Supplementary
Fig. S4).
An initial burst was measured with all three of the formulations F1,
F2, and F3 shown in Fig. 4, which, as expected from the stability studies,
showed that IPV could be recovered after the initial steps of micro-
sphere fabrication (emulsiﬁcation and drying). However, the secondary
burst of release, which started after approximately 25 days, was very
low for F1 particles containing gelatin as an excipient, with some slight
Fig. 4. Sugar-based excipients promote long-term IPV release fromPLGAmicrospheres. IPV encapsulated in PLGAmicrosphereswith gelatin (A–B)was released in a strong initial burst. For
particles containing sucrose, MSG, andMgCl2 (C–D) ormaltodextrin,MSG, andMgCl2 (E–F), a second burst of type 2 IPVwas observed around 25–39 days, with very little of types 1 and 3
released after the initial burst. Graphs in B, D, and F show cumulative IPV release.
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starting at 25–28 days, was much more clearly observed from F2 and
F3 particles containing either sucrose or maltodextrin along with MSG
andMgCl2, with this secondary release phase consistingmainly of sero-
type 2 and only very low levels of serotypes 1 and 3. This multi-phasic
release is typical for large macromolecules encapsulated in PLGA-
based particles. IPV virions very near the surface of the particles are re-
leased quickly in an initial burst, and there is a delay of release while
water enters the microsphere matrix and begins to degrade the PLGA
by bulk erosion. Once enough of the PLGA has degraded for channels
to form through the microsphere matrix, release accelerates again in a
second burst.
Gelatin-containing particles showed a large initial burst but no sig-
niﬁcant release thereafter, with nearly 100% of all release occurring in
the ﬁrst few days (Fig. 4A-B). This was expected and validates use of
the liquid incubation assay used to measure stability: gelatin alone as
an excipient improved IPV recovery after emulsiﬁcation and drying
but showed very little ability to stabilize IPV in an aqueous, 37 °C envi-
ronment over time. Although gelatin has been found in some systems to
stabilize certain antigens against stresses of heat and moisture [35],
other studies have reported ﬁndings similar to ours, with gelatin and
viscosity-increasing agents protecting proteins from interfacial tension
[27] but having a very low or even a negative effect on protein stability
[36,37]. Both sucrose and maltodextrin in combination with MSG and
MgCl2 are superior for long-term IPV stability inside PLGA particles inTable 3
IPV encapsulation efﬁciency inmicrospheres. Percent encapsulation efﬁciency is normalized to t
actual measured loading. Data are represented as mean ± standard deviation (n = 3).
Formulation IPV encapsulation efﬁciency (%) Total IPV encapsu
Type 1 Type 2 Type 3 Type 1
F1 84 ± 4 81 ± 5 77 ± 2 27 ± 1
F2 69 ± 4 67 ± 4 67 ± 5 22 ± 1
F3 68 ± 7 69 ± 11 64 ± 6 22 ± 2
F4 66 ± 5 63 ± 6 70 ± 6 21 ± 1
F5 74 ± 4 75 ± 4 69 ± 5 24 ± 1
F6 82 ± 12 83 ± 9 83 ± 2 26 ± 4
F7 70 ± 8 71 ± 4 72 ± 7 22 ± 2
F8 75 ± 6 73 ± 3 70 ± 2 24 ± 2
F9 61 ± 6 60 ± 5 60 ± 10 20 ± 2an aqueous 37 °C buffer, conﬁrming the long-term thermostability re-
sults seen independently of PLGA particles. As a result, combinations
of sucrose or maltodextrin with MSG and MgCl2 were pursued for fur-
ther study. However, even with the carbohydrate-based excipients,
only type 2 IPV was detected in the second burst in high amounts
(Fig. 4C–F), and very little of types 1 and 3 were released after the ﬁrst
four days.
Formulations F1, F2, and F3 all showed similar encapsulation efﬁ-
ciencies (Table 3), with 77–84% encapsulation of each serotype in the
F1 gelatin-containing particles and 64–69% encapsulation in the parti-
cles containing sugar-based excipients. Because of the low IPV mass
concentration and the high excipient:IPV mass ratios used in these mi-
crospheres, non-speciﬁc protein assays and chromatographic methods
could not be used to quantify protein release, and an ELISA speciﬁc for
denatured IPV was used instead, and the small differences in the mea-
sured IPV encapsulation in F1 particles could be due in part to the
minor effect of the excipient mixtures on the binding equilibrium be-
tween IPV and ELISA antibodies. It is likely, therefore, that the differ-
ences in release seen in F1 particles compared to F2 and F3 are due
primarily to long-term stabilization capabilities of the excipient mix-
tures.Moreover, for each formulation, all three serotypeswere encapsu-
lated to a similar extent, which is expected from the physical and
chemical similarity of the three types of virions. Thus, the very low
amount of delayed release of types 1 and 3 suggests that IPV stability
in PLGA microspheres during the release study was affected by otherheoretical initial loading. Percent recovery of D-antigen during release is normalized to the
lated (number of doses/50 mg) D-antigen recovery during release (%)
Type 2 Type 3 Type 1 Type 2 Type 3
26 ± 2 25 ± 1 2.3 ± 0.3 4.6 ± 0.4 4.1 ± 0.3
21 ± 1 21 ± 2 2.7 ± 0.1 5.6 ± 0.6 4.2 ± 0.2
22 ± 3 20 ± 2 4.6 ± 0.2 9.1 ± 0.4 4.9 ± 0.3
20 ± 2 22 ± 2 2.4 ± 0.3 23 ± 1.2 2.2 ± 0.2
24 ± 1 22 ± 2 0.4 ± 0.2 14 ± 0.5 4.1 ± 0.5
27 ± 3 27 ± 1 4.6 ± 0.9 7.5 ± 0.9 4.5 ± 0.3
23 ± 1 23 ± 2 9.0 ± 0.4 8.8 ± 0.7 8.3 ± 0.7
23 ± 1 23 ± 1 6.7 ± 0.4 8.2 ± 1.2 7.5 ± 0.9
19 ± 2 19 ± 3 1.1 ± 1.2 24 ± 2.3 8.3 ± 0.9
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which showed up to 70–72% recovery of types 1 and 3 after 1 month.
Therefore, stresses speciﬁc to the PLGA microenvironment were
explored.
3.5. IPV pH-sensitivity studies
Because PLGA degrades into lactic acid and glycolic acid, the pH
around and within the microspheres decreases dramatically over time
in an aqueous environment, with some studies ﬁnding that the internal
pH of PLGA-based microspheres can reach as low as 1.5 [38]. Because
IPV is trapped inside the particles for weeks to months before being re-
leased, it was necessary to assess its sensitivity to the pH extremes that
it would experience over the relevant time period. Initial studies used
ﬂuorescently labeled IPV (AF680-IPV) encapsulated in PLGA502H mi-
crospheres with 10 μL of 20% sucrose, 17% MSG, and 17% MgCl2 as the
excipients, and IPV release was measured by ﬂuorescence instead of
by an antibody-based assay, thereby allowing total IPV release kinetics
to be assessed without taking into account IPV stability over time.
As seen in Fig. 5A, the pH of the release medium at each time point
steadily decreased over the course of the release study, reaching b4
after 16 days of release, indicating that PLGA is degrading and acidifying
the release buffer over this period. Following this, the pH slowly rises
again and ﬁnally stabilizes at 7.0–7.4 after 30 days. It is important to
note that the pH reported is that of the release medium, i.e. the pH out-
side the particles. In contrast, the internal pH of microspheres can be af-
fected by various factors, including the degree to which the particles
swell with water, buffering salts, and the rate of diffusion of water, ex-
cipients, and protons into and out of the particles. The external pH canFig. 5. Low pH in degrading PLGAmicrospheres decreases IPV stability over time. The pH surrou
measured just before IPV is released inmeasurable amounts (A). The difference in release kinet
that IPV would be trapped inside the degrading particles before acidic protons are released an
particularly type 1, is very unstable in even slightly basic or acidic pH after 2 days (C) or 7 da
particles.critically affect the stability of IPV that has been released and remains
in the releasemedium for hours or days until a timepoint is taken; how-
ever, it does not precisely reﬂect the internal microsphere pH, which
could be particularly important to the stability of IPV that is yet
unreleased. The continual decrease in pH of the release medium over
the ﬁrst 2–3 weeks followed by its steady rise seems to indicate that
acidic protons can diffuse out of the particles, but it is reasonable to as-
sume that the proton concentration within the particles in the ﬁrst
weeks is equal to or higher than that in the outside medium. Although
the buildup of internal acidity contributes to the characteristic, pulsatile
pattern of release from PLGA particles, it could also contribute to IPV in-
stability at later time points.
When AF680-IPV is encapsulated, a large portion is released within
the ﬁrst few days (41% within 2 days), followed by little or no release
and then a secondburst of release between 18 and 35 days. Importantly,
a large amount of the IPV has not yet been released from the micro-
sphere when the pH is measured to be at its lowest in the external
environment, implying that the internal pH near the unreleased IPV is
likely to be very low as well.
It is possible that the IPV is released in a later second burst than the
acidic protons because of the difference in size between the two. Each
IPV virion has a molecular mass of approximately 8500 kDa [39]. It is
reasonable that amuch larger macromolecule requires more of the par-
ticle to have degraded, forming larger channels through the polymer
matrix, in order to be able to diffuse into the release medium. This hy-
pothesis was tested by comparing the release kinetics of AF680-IPV,
AF680-BSA, and AF680 free dye, with approximate molecular weights
of 8500 kDa, 67 kDa, and 1 kDa, respectively (Fig. 5B). The shift in the
second burst of release is clearly related to the size of the moleculending PLGAmicrospheres decreases over the course of a release study, with the lowest pH
ics between cargo of varyingmolecular weight from approximately 1 to 8500 kDa suggests
d would therefore experience a low-pH environment (B). Stability studies show that IPV,
ys (D) of incubation at 37 °C, further emphasizing the need to relieve the acidity within
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IPV releases later than the small molecules, it is likely to be trapped in
the acidic internal environment for longperiods of time before it can dif-
fuse into the release medium.
Whether IPV is released or still trapped in the PLGAmicrospherema-
trix, the surrounding pH can have an important effect on its stability
(Fig. 5C–D). At low concentrations, as IPV would be after release into
the buffer, type 1 IPV loses stability rapidly even at neutral (7.4) pH,
with only 58 ± 1% remaining after 2 days at 37 °C and 40 ± 2% after
7 days. Even small deviations from neutral pH cause type 1 IPV to dena-
ture evenmore quickly, with 5±1% and 11±2% recovery at 37 °C after
7 days at pH 8 and 6, respectively. D-antigen was b5% for all serotypes
after incubation for 2 or more days at pH 4.5. As seen in the earlier ex-
periments, types 2 and 3 both tended to be more stable than type 1,
with no statistically signiﬁcant loss in D-antigen content after 7 days
of incubation at pH 7.4. However, type 2 stability decreased upon incu-
bation in an acidic medium, with only 31 ± 5% recovery after 7 days at
pH 6. While type 3 appeared to be slightly less sensitive to acid than
types 1 and 2 (63 ± 4% recovery after 7 days at pH 6), lost stability
when kept in even slightly basic pH (64 ± 7% recovery after 7 days at
pH 8). The sensitivity of IPV to basic as well as acidic environments is
important for understanding how PLGA degradation affects the IPV
cargo and how best to compensate for acid buildup using basic
excipients.
3.6. Basic small molecules reduce IPV damage over time due to PLGA
degradation products
In order to combat IPV loss due to increasing acidity from the
degrading PLGA, basic excipients were added to themicrosphere for-
mulations. Arginine, a basic amino acid that has been found to stabi-
lize viruses and vaccines [40,41], was dissolved in the same aqueous
phase as the IPV and excipients. Mg(OH)2, a basic and poorly solubleFig. 6. Co-encapsulation of basic excipients improves IPV stability at late time points. Adding
without basic excipients. However, neither type 1 nor type 3 was able to approach the high relsalt [42,43], can buffer the acidic environment and was dispersed
through the ﬁrst PLGA-containing oil phase by sonication. Neither
of these additives showed a strong effect on encapsulation efﬁciency
(Table 3).
Some type 1 or type 3 release was seen in the secondary burst of
Mg(OH)2- and arginine-containing particles (Fig. 6), formulations F4
and F5, respectively. In the case of both particles, the peaks correspond-
ing to both the initial and secondary bursts are broader, resulting in less
narrow pulses of release. Because the characteristic pulsatile release
from PLGA particles is due in part to the accelerated degradation of
the ester bond as acid accumulates within these particles, it is unsur-
prising that molecules that reduce accumulation of acid would also
result in more continuous release. It is signiﬁcant that high amounts
of type 2 IPV still remained stable and in D-antigen form as long as
40–50 days after the start of the release study.
From Mg(OH)2-containing particles, type 1 release in the second
burst was 4.4-fold higher than from particles with only sucrose, MSG,
and MgCl2; type 2 also had a 6.4-fold improvement in the second
burst, and type 3 had only 0.6-fold as much release in the second
burst (Table 4). From arginine-containing particles, type 1 release in
the second burst was not improved, but types 2 and 3 saw 5.1- and
2.3-fold greater release, respectively, in the second burst. Moreover,
type 1 IPV shows very little release at all, initially or at later time points,
from arginine-containing particles. Because arginine is basic andwater-
soluble, it is possible that it raises the pH of the aqueous phase too far
above neutral, causing denaturation of themore sensitive IPV serotypes.
In addition, the type 1 and 3 secondary bursts, although higher than in
previous formulations, are still quite small, and only type 2was released
in amounts high enough for a human therapeutic dose (Table 4) equiv-
alent to two standard clinical boluses. Therefore, while F4 and F5 may
not be ideal for stabilization and extended release of all three IPV sero-
types, these formulations could be highly effective for stabilization of
type 2 IPV if monovalent IPV were to be encapsulated.Mg(OH)2 (A–B) or arginine (C–D) improved type 1 and 3 stability compared to particles
ease seen with type 2. Cumulative release normalized to total release is shown in B and D.
Table 4
Percent of total IPV release measured during the ﬁrst and second bursts.
Formulation
Initial burst (%) Second burst (%)
Number of human doses released in total
by 50 mg particles
Type 1 Type 2 Type 3 Type 1 Type 2 Type 3 Type 1 Type 2 Type 3
F1 90 64 88 3 14 2 0.6 1.2 1.0
F2 86 42 71 8 46 22 0.6 1.2 0.9
F3 90 53 76 6 42 17 1.0 2.0 1.0
F4 49 13 60 40 77 25 0.5 4.6 0.5
F5 67 9 34 27 83 53 0.1 3.4 0.9
F6 77 66 61 22 31 36 1.2 2.0 1.2
F7 69 53 62 23 37 29 2.0 2.0 1.9
F8 65 43 52 20 54 18 1.6 1.9 1.7
F9 20 46 53 70 50 34 0.2 4.6 1.6
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To address the hypothesis that accumulation of acid inside the parti-
cles was still one of themajor problems for achieving late release of IPV,
Eudragit E PO (EPO) was doped into the polymer-containing ﬁrst oil
phase. Because of the amines in its backbone, EPO can act as a base
and help to buffer the internal environment. However, unlike small sol-
uble molecules such as arginine, EPO is poorly water soluble at neutral
or slightly acidic pH, which prevents it from causing denaturation of
IPV by making the aqueous compartment excessively basic; at pH b 3,
EPO becomes soluble in aqueous solutions at 20 mg/mL or lower con-
centrations. Therefore, when it is blended with PLGA and incorporated
into the microspheres, EPO does not initially cause major changes in
pH, as it is incorporated into the aprotic organic phase during fabrica-
tion. However, upon hydration of the microspheres during in vitro re-
lease studies or after in vivo injection, EPO causes an increase in the
local pH of the PLGA-containing compartment, which accelerates local
PLGA degradation by base-catalyzed hydrolysis. As PLGA is hydrolyzed,
EPO becomes progressively more protonated as the environmentFig. 7. Eudragit E-doped particles show release of stable IPV at 2–3 weeks. By incorporating
accumulating acid and be released in stable form. Decreasing the EPO concentration from 7
Adjusting the pH by adding arginine (J–L) also slowed the second burst of release.increases in acidity, and when acidic protons accumulate to a critical
level, EPO dissolves into the aqueous phase and can then diffuse out of
the microsphere. Because EPO forms part of the microsphere matrix,
its dissolution creates channels large enough through which protons
as well as the cargo of interest, IPV, can diffuse out, rather than being
conﬁned within the acidiﬁed particle.
We found that doping in EPO signiﬁcantly improved the release of
stable IPV, particularly types 1 and 3, after several days or even weeks
(Fig. 7). For instance, formulation F7, containing maltodextrin, MSG,
MgCl2, and 5% EPO (Fig. 7D-F), shows improvements of 7.8-, 0.9-, and
3.2-fold in type 1, 2, and 3 release, respectively, in the second burst.
The release proﬁle with this method is much more pulsatile than
many of the proﬁles achieved before, with the second burst largely tak-
ing place over a span of approximately 1 week or less (Fig. 7). This is
likely because the inclusion of EPO accelerates degradation of the
PLGA, resulting in complete or near-complete IPV release within a
short period of time. All EPO-containing formulations F6–F9 had similar
encapsulation efﬁciencies ranging from 60 to 83% for each serotype
(Table 3). Particularly in the cases of F7 and F8, with 5% and 3% EPO,the basic, acid-soluble EPO into the PLGA-based particles, IPV could be protected from
.5% (A–C) to 5% (D–F) to 3% (G–I) allowed the kinetics of the second burst to be tuned.
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stable types 1 and 3 over the course of 1 month of release was much
higher than in previously tested formulations.
Interestingly, using EPO as a dopant allows the release kinetics to be
tuned easily by simply altering the ratio of EPO to PLGA. With 7.5% EPO
added to the formulation, the secondary burst peaks at approximately
11 days, while 5% and 3% EPO result in a second peak after 14–18 days
and 25 days, respectively. Addition of a basic excipient, arginine, to the
formulation delays the acidiﬁcation and therefore the EPO dissolution
in the surrounding aqueous solution, resulting in a second peak after
32 days. The ability to tune kinetics greatly increases the utility of this
technology, as it allows the antigen to be released at desired time points
over the course of a month.
Importantly, the amount of IPV released by the EPO-containing for-
mulations in both the initial and secondary bursts approaches or ex-
ceeds the amount of IPV normally delivered in two bolus doses over
1–2 months by current clinical standards (Fig. 8). For example, from
50 mg of F7, with maltodextrin, MSG, MgCl2 and 5% EPO as excipients,
1.4, 1.1, and 1.2 human doses of types 1, 2, and 3, respectively, were re-
leased in an initial burst, with 0.5, 0.8, and 0.6 doses released in a sepa-
rate second burst. This indicates that these particles are able to release a
therapeutically relevant amount of vaccine within the 1–2 month
timeframe that is currently recommended by the WHO. These results
are very promising, as the amount of injected particles can be easily ad-
justed so that the formulations release exactly onehuman dose per time
point.
3.8. Efﬁcacy of IPV-containing microspheres in vivo
While in vitro studies showed that microspheres such as formula-
tions F7 and F8 could release pulses of IPV over onemonth, the ability
to elicit an immune response in vivo is critical to their potential use asFig. 8. Formulations F7 and F8 release therapeutic doses of IPV in two distinct bursts. Both of th
dosing regimen consisting of two bolus injections. A and C show the number of human doses re
and D show the cumulative number of doses released.a clinical vaccine. To show their efﬁcacy in a rodent model, rats were
injected IM with boluses of IPV, mimicking the current clinical ad-
ministration method, or with IPV-containing microsphere formula-
tion F8.
As expected, injecting a single bolus containing two rat doses elicited
binding antibodies to all three serotypes (Fig. 9). However, when the
boluses are spread over time, with one rat dose administered initially
(t = 0) and then again 4 weeks later, the resulting antibody response
equals or exceeds that of a single bolus, highlighting the importance of
a second antigen presentation for vaccine efﬁcacy. Interestingly, F8 mi-
crospheres elicited a strong antibody response against type 1 IPV and,
even at early time points, before all of its cargo is expected to have
been released, surpassed the humoral response seen from the single
bolus containing the full two rat doses. While this improvement over
the standard bolus is not seen to a statistically signiﬁcant extent in the
type 2 and type 3 responses, it is interesting to note that the antibody
titers initially elicited by a single bolus are similar to those elicited by
the F8microsphere formulation, which contains the same total IPV dos-
age but has not yet released all of its cargo.
This apparent adjuvant effect of the microspheres has been well-
documented in other systems [44–46] and may play a role in the effec-
tiveness of the current formulations studied here for IPV delivery. Al-
though several mechanisms may contribute to this effect, co-injection
of a boluswith blankmicrospheres showed onlyminor differences com-
pared to the bolus alone (Fig. 8), suggesting that the adjuvancy is not
caused simply by the presence of the particles themselves or any non-
speciﬁc reaction to the particles or their degradation products. No
clear signs of toxicity were observed after injection with microspheres.
As others have found that the kinetics of antigen presentation can have
an important effect on the immune response [47,48], it is likely that the
particular release kinetics of IPV frommicrospheres contribute to the in-
duction of a stronger antibody response compared with a single bolus.e leading EPO-containing formulations release the equivalent amount of IPV as a standard
leased by an injectable mass of particles, with one human dose deﬁned as a single bolus; B
Fig. 9. Formulation F8 elicits non-inferior immune response compared to bolus injections of IPV.Humoral immune response elicited by a single bolus of IPV (Δ open triangle), a single bolus
of IPV co-injected with empty particles (✕ cross), two boluses of IPV (☐ open square), or IPV encapsulated in F8 microspheres (■ solid square) was measured in rats. Antibody titers
speciﬁc for type 1 (A), type 2 (B), or type 3 (C) poliovirus are plotted on a log-2 scale as geometric mean ± 95% conﬁdence interval. Statistically signiﬁcant differences from the
positive control (two boluses of IPV) are marked as: * b 0.05 and ** b 0.01 (IPV encapsulated in F8 microspheres); § b 0.05 and §§ b 0.01 (single bolus co-injected with empty
particles); and # b 0.05 and ## b 0.01 (single bolus).
112 S.Y. Tzeng et al. / Journal of Controlled Release 233 (2016) 101–113The boluses administered 4 weeks apart do show a strong increase
in antibody titers after the second dose. For types 1 and 2, boluses ad-
ministered 4 weeks apart elicited a signiﬁcantly stronger immune re-
sponse than a single bolus alone at all time points. However, the titers
elicited even by two boluses again fall more quickly than those elicited
by themicrospheres, and 10 weeks after the initial injection, antibodies
against the IPV boluses were statistically equivalent to those against F8
for all three serotypes. Interestingly, despite the pulsatile release proﬁle
of F8microspheres seen in vitro, in vivo they elicited high antibody titers
within a few weeks and then maintained this high level for several
weeks, in contrast to the distinct inﬂection at the time of the booster
that is seen in the group immunized with two separate boluses. This
may be a consequence of the broader peaks of IPV release by F8 micro-
spheres compared to the very brief IPV presentation in bolus groups.
Most importantly, however, this broad release may contribute to a pos-
itive effect on the immune response.4. Conclusions
Single-injection vaccines are of high interest in the global health
ﬁeld to improve compliance and aid in eradication efforts. IPV, which
possesses poor thermostability on its own and in current clinical formu-
lations, was shown here to havemarkedly higher stability at 37 °C upon
incubation with excipients containing a carbohydrate, MSG, and MgCl2,
with increased recoveries of 2.4-fold after 1 month for type 1 IPV. With
the aid of excipients, IPV could be encapsulated in PLGA-based micro-
spheres and released in vitro in two bursts separated by approximately
1month. In addition to thermostabilizing excipients, basic, cationic dop-
ant Eudragit E polymer caused clinically relevant amounts of stable IPV
release upon degradation of the PLGAmatrix, thusminimizing the num-
ber of required vaccine administrations. Critically, in vivo studies
showed that this technology can induce a potent immune response in
animal models by measurement of IPV-speciﬁc binding antibodies,
with a quick induction and long duration of high antibody titers. With
a single injection, the topmicrosphere formulation showed non-inferior
antibody response compared to two separate bolus injections after 10
weeks. An ideal vaccine product using this platform could potentially
be stored in dry form, reconstituted before use, and injected into a pa-
tient, requiring only a single visit from a healthcare professional for
long-lasting protective immunity. Therefore, this technology can poten-
tially serve as an important tool to aid in the eradiation of polio and
other infectious diseases for the improvement of global health.Acknowledgements
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